Expense Fund. Upon the Closing, Parent shall, on behalf of the Holders, wire to the Representative $50,000 (the “Expense Fund Amount”). The Expense Fund Amount shall be held by the Representative in a segregated client account and shall be used (a) for the purposes of paying directly or reimbursing the Representative for any Representative Expenses incurred pursuant to this Agreement or the Representative Engagement Agreement, or (b) as otherwise determined by the Advisory Group (the “Expense Fund”). The Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Expense Fund other than as a result of its gross negligence or willful misconduct. The Representative is not acting as a withholding agent or in any similar capacity in connection with the Expense Fund and has no tax reporting or income distribution obligations. The Holders will not receive any interest on the Expense Fund and assign to the Representative any such interest. Subject to Advisory Group approval, the Representative may contribute funds to the Expense Fund from any CVR Proceeds or other amounts otherwise distributable to the Holders. As soon as reasonably determined by the Representative that the Expense Fund is no longer required to be withheld, the Representative shall distribute the remaining Expense Fund (if any) to the Rights Agent and/or Parent, as applicable, for further distribution to the Holders.
Appears in 2 contracts
Sources: Contingent Value Rights Agreement (Rain Oncology Inc.), Merger Agreement (Rain Oncology Inc.)
Expense Fund. Upon At the Closing, Parent shall, on behalf of the Holders, shall wire to the Representative $50,000 (the “Expense Fund Amount”). The Expense Fund Amount shall be held by the Representative in a segregated client account and shall be used (ai) for the purposes of paying directly or reimbursing the Representative for any Representative Expenses Losses incurred pursuant to this Agreement or (ii) paying directly, or reimbursing the Representative Engagement Agreementfor, or (b) as otherwise determined by any third party expenses pursuant to this Agreement and the Advisory Group agreements ancillary hereto (the “Expense Fund”). The Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Expense Fund other than as a result of its the Representative’s gross negligence or willful misconduct. The Representative will hold these funds separate from its corporate funds, will not use these funds for any corporate purposes and will not voluntarily make these funds available to its creditors in the event of bankruptcy. The Representative is not acting as a withholding agent or in any similar capacity in connection with the Expense Fund Fund, and has no tax reporting or income distribution obligations. The Holders Sellers will not receive any interest or earnings on the Expense Fund and irrevocably transfer and assign to the Representative any such interest. Subject to Advisory Group approval, the Representative may contribute funds to the Expense Fund from any CVR Proceeds interest or other amounts otherwise distributable to the Holdersearnings. As soon as reasonably determined by the Representative that the Expense Fund is no longer required to be withheld, the Representative shall distribute deliver the remaining Expense Fund (if any) to the Rights Paying Agent and/or Parent, as applicable, for further distribution to the HoldersSellers. For tax purposes, the Expense Fund will be treated as having been received and voluntarily set aside by the Sellers at the time of Closing.
Appears in 1 contract
Sources: Agreement and Plan of Merger (Lexeo Therapeutics, Inc.)
Expense Fund. Upon Following the Closingfirst Disposition and Purchaser’s receipt of Gross Proceeds, Parent shall, on behalf of the Holders, Purchaser shall wire to the Representative $50,000 of the CVR Proceeds that become payable to the Holders from such Disposition (the “Expense Fund Amount”)) by the CVR Payment Date. The Expense Fund Amount shall be held by the Representative in a segregated client account and shall be used (ai) for the purposes of paying directly or reimbursing the Representative for any Representative Expenses incurred pursuant to this Agreement or the Representative Engagement Agreement, or (bii) as otherwise determined by the Advisory Group (the “Expense Fund”). The Representative is not providing any investment supervision, recommendations or advice and shall have no responsibility or liability for any loss of principal of the Expense Fund other than as a result of its gross negligence or willful misconduct. The Representative is not acting as a withholding agent or in any similar capacity in connection with the Expense Fund and has no tax reporting or income distribution obligations. The Holders will not receive any interest on the Expense Fund and assign to the Representative any such interest. Subject to Advisory Group approval, the Representative may contribute funds to the Expense Fund from any CVR Proceeds or other amounts otherwise distributable to the Holders. As soon as reasonably determined by the Representative that the Expense Fund is no longer required to be withheld, the Representative shall distribute the remaining Expense Fund (if any) to the Rights Agent and/or ParentPurchaser, as applicable, for further distribution to the Holders.
Appears in 1 contract
Sources: Contingent Value Rights Agreement (Concentra Merger Sub II, Inc.)